My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Halozyme Therapeutics (HALO)
NASDAQ:HALO
HALO nasdaq
United States
Halozyme

Halozyme Stock Analysis & Ratings

Halozyme Stock Analysis Overview

Smart Score
8
Outperform
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Halozyme stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

HALO

HALO Stock Stats

Previous Close$36.9
Open$36.98
Bid38.1 x 300
Ask46.26 x 100
Today’s Range$36.91 - $38.67
52-Week Range$27.21 - $56.40
Volume733.19K
Average Volume797.59K
Market Cap$5.47B
Beta1.44
P/E Ratio23.5
EPS1.57
Earnings DateNov 08, 2021

Company Description

Halozyme Therapeutics

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Sector
Healthcare
Industry
Biotechnology
CEO
Helen I. Torley
Employees
136
ISIN
US40637H1095
Address
11388 Sorrento Valley Road, San Diego, CA, 92121, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

HALO FAQ

What was Halozyme’s price range in the past 12 months?
Halozyme lowest stock price was $27.21 and its highest was $56.40 in the past 12 months.
    What is Halozyme’s market cap?
    Halozyme’s market cap is $5.47B.
      What is Halozyme’s price target?
      The average price target for Halozyme is $56.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $66.00 ,the lowest forecast is $50.00. The average price target represents 45.76% Increase from the current price of $38.42.
        What do analysts say about Halozyme?
        Halozyme’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
          When is Halozyme’s upcoming earnings report date?
          Halozyme’s upcoming earnings report date is Nov 08, 2021 which is in 24 days.
            How were Halozyme’s earnings last quarter?
            Halozyme released its earnings results on Aug 09, 2021. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.435 by $0.185.
              Is Halozyme overvalued?
              According to Wall Street analysts Halozyme’s price is currently Undervalued.
                Does Halozyme pay dividends?
                Halozyme does not currently pay dividends.
                What is Halozyme’s EPS estimate?
                Halozyme’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Halozyme have?
                Halozyme has 142,330,000 shares outstanding.
                  What happened to Halozyme’s price movement after its last earnings report?
                  Halozyme reported an EPS of $0.62 in its last earnings report, beating expectations of $0.435. Following the earnings report the stock price went up 1.827%.
                    Which hedge fund is a major shareholder of Halozyme?
                    Among the largest hedge funds holding Halozyme’s share is Fisher Asset Management LLC. It holds Halozyme’s shares valued at 42M.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis